MEPROBAMATE

Post-LOE

meprobamate

GenexGen

ANDAORALTABLET

Approved

Mar 1982

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

MEPROBAMATE (meprobamate) by GenexGen is clinical pharmacology meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety, anxiety and 1 more indications. First approved in 1982.

Drug data last refreshed 21h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system.

Indications (3)

anxiety disorders for the short-term relief of the symptoms of anxiety

Worked on MEPROBAMATE at GenexGen? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.